Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Sialic acid binding Ig-like lectin 22, pseudogene (SIGLEC22P)
- Target
- SIGLEC22P
- Molecular classification
- Other (Pseudogene; not an active protein-coding gene)
01
Overview
Sialic acid binding Ig-like lectin 22, pseudogene (SIGLEC22P) is a human pseudogene, meaning it is a non-functional segment of DNA that closely resembles the functional members of the sialic acid-binding immunoglobulin-like lectin (SIGLEC) family but does not encode a functional protein. It is most closely related in sequence to CD33 (SIGLEC3) and resides about 13.5 kb away from CD33 on the genome. While it does not serve any physiological function as a protein, it can act as a template for gene conversion during DNA double-strand break repair, as documented during CRISPR-Cas9 mediated genome editing: portions of SIGLEC22P have been copied into CD33 in editable cell lines, resulting in chimeric protein sequence and loss of clinical antibody recognition. This property may present technical complications in gene-editing experiments but has no established physiological or therapeutic role.
- Other names
- SIGLECP6
02
Mechanism of action
None (No drug mechanism of action exists for this non-coding pseudogene)
03
Biological functions
None (SIGLEC22P is a pseudogene, and does not encode a functional protein. However, it may participate in rare gene conversion events during DNA repair, as seen with off-target CRISPR-Cas9 editing)
04
Disease associations
Other (Pseudogene itself has no known direct disease role. Indirectly, has contributed to off-target effects in gene editing of related genes such as CD33)
05
Safety considerations
Unintended gene conversion during genome editing may introduce mutations from SIGLEC22P into closely related functional genes (such as CD33), which may affect the epitope recognized by therapeutic antibodies (e.g., gemtuzumab), complicating genome editing or therapeutic antibody targeting in a research or clinical context
06
Interacting drugs
None (No drugs are known to interact with SIGLEC22P, as it does not produce a protein)
07
Biomarkers
None (SIGLEC22P is not used as a biomarker)
Beyond the preview
Go deeper on Sialic acid binding Ig-like lectin 22, pseudogene (SIGLEC22P).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sialic acid binding Ig-like lectin 22, pseudogene (SIGLEC22P).